TP53 and neoplasm: In the current study, we uncovered tumor-intrinsic differences between two SCC tumor lines (TAb2 and TCh3), both of which harbor TP53 deletion and PIK3CA hyperactivation, yet they responded to anti-PD-L1 therapy differently.